Skip to Main Content

Author Details

Gabriela Alexe
Dana-Farber Cancer Institute
2004
76
37
Antoine Forget (CM4AI)
PMIDPaper TitleJournal TitlePublished Year
36398965Transcriptional Antagonism by CDK8 Inhibition Improves Therapeutic Efficacy of MEK Inhibitors.Cancer Res2023
36398965Transcriptional Antagonism by CDK8 Inhibition Improves Therapeutic Efficacy of MEK Inhibitors.Cancer Res2023
37648673DHODH: a promising target in the treatment of T-cell acute lymphoblastic leukemia.Blood Adv2023
37648673DHODH: a promising target in the treatment of T-cell acute lymphoblastic leukemia.Blood Adv2023
34341479Targeting serine hydroxymethyltransferases 1 and 2 for T-cell acute lymphoblastic leukemia therapy.Leukemia2022
35710782Identification of an Epi-metabolic dependency on EHMT2/G9a in T-cell acute lymphoblastic leukemia.Cell Death Dis2022
35817829Transition to a mesenchymal state in neuroblastoma confers resistance to anti-GD2 antibody via reduced expression of ST8SIA1.Nat Cancer2022
35474100Cystine uptake inhibition potentiates front-line therapies in acute myeloid leukemia.Leukemia2022
35405016Unleashing Cell-Intrinsic Inflammation as a Strategy to Kill AML Blasts.Cancer Discov2022
34341479Targeting serine hydroxymethyltransferases 1 and 2 for T-cell acute lymphoblastic leukemia therapy.Leukemia2022
35298000Mitochondrial Dysfunction Is a Driver of SP-2509 Drug Resistance in Ewing Sarcoma.Mol Cancer Res2022
35245447The proteogenomic subtypes of acute myeloid leukemia.Cancer Cell2022
35710782Identification of an Epi-metabolic dependency on EHMT2/G9a in T-cell acute lymphoblastic leukemia.Cell Death Dis2022
35474100Cystine uptake inhibition potentiates front-line therapies in acute myeloid leukemia.Leukemia2022
35405016Unleashing Cell-Intrinsic Inflammation as a Strategy to Kill AML Blasts.Cancer Discov2022
35817829Transition to a mesenchymal state in neuroblastoma confers resistance to anti-GD2 antibody via reduced expression of ST8SIA1.Nat Cancer2022
35245447The proteogenomic subtypes of acute myeloid leukemia.Cancer Cell2022
35298000Mitochondrial Dysfunction Is a Driver of SP-2509 Drug Resistance in Ewing Sarcoma.Mol Cancer Res2022
34129824STAG2 loss rewires oncogenic and developmental programs to promote metastasis in Ewing sarcoma.Cancer Cell2021
34129824STAG2 loss rewires oncogenic and developmental programs to promote metastasis in Ewing sarcoma.Cancer Cell2021
33790022Targeting acute myeloid leukemia dependency on VCP-mediated DNA repair through a selective second-generation small-molecule inhibitor.Sci Transl Med2021
34329586TRIM8 modulates the EWS/FLI oncoprotein to promote survival in Ewing sarcoma.Cancer Cell2021
33790022Targeting acute myeloid leukemia dependency on VCP-mediated DNA repair through a selective second-generation small-molecule inhibitor.Sci Transl Med2021
34329586TRIM8 modulates the EWS/FLI oncoprotein to promote survival in Ewing sarcoma.Cancer Cell2021
32826232The Folate Cycle Enzyme MTHFR Is a Critical Regulator of Cell Response to MYC-Targeting Therapies.Cancer Discov2020
31771968Resistance Mechanisms to SYK Inhibition in Acute Myeloid Leukemia.Cancer Discov2020
32826232The Folate Cycle Enzyme MTHFR Is a Critical Regulator of Cell Response to MYC-Targeting Therapies.Cancer Discov2020
31771968Resistance Mechanisms to SYK Inhibition in Acute Myeloid Leukemia.Cancer Discov2020
30390009Creatine kinase pathway inhibition alters GSK3 and WNT signaling in EVI1-positive AML.Leukemia2019
31817488Descriptors for High Throughput in Structural Materials Development.High Throughput2019
30397176A Combination CDK4/6 and IGF1R Inhibitor Strategy for Ewing Sarcoma.Clin Cancer Res2019
30390009Creatine kinase pathway inhibition alters GSK3 and WNT signaling in EVI1-positive AML.Leukemia2019
31039138Therapeutic discovery for marrow failure with MDS predisposition using pluripotent stem cells.JCI Insight2019
30979745High-throughput Chemical Screening Identifies Focal Adhesion Kinase and Aurora Kinase B Inhibition as a Synergistic Treatment Combination in Ewing Sarcoma.Clin Cancer Res2019
31447068Single-cell cloning of human T-cell lines reveals clonal variation in cell death responses to chemotherapeutics.Cancer Genet2019
31817488Descriptors for High Throughput in Structural Materials Development.High Throughput2019
31447068Single-cell cloning of human T-cell lines reveals clonal variation in cell death responses to chemotherapeutics.Cancer Genet2019
31039138Therapeutic discovery for marrow failure with MDS predisposition using pluripotent stem cells.JCI Insight2019
30979745High-throughput Chemical Screening Identifies Focal Adhesion Kinase and Aurora Kinase B Inhibition as a Synergistic Treatment Combination in Ewing Sarcoma.Clin Cancer Res2019
30397176A Combination CDK4/6 and IGF1R Inhibitor Strategy for Ewing Sarcoma.Clin Cancer Res2019
29328122Model-assisted measuring method for periodical sub-wavelength nanostructures.Appl Opt2018
30504235The kinases IKBKE and TBK1 regulate MYC-dependent survival pathways through YB-1 in AML and are targets for therapy.Blood Adv2018
30537514Resistance to Epigenetic-Targeted Therapy Engenders Tumor Cell Vulnerabilities Associated with Enhancer Remodeling.Cancer Cell2018
30045945Genome-scale CRISPR-Cas9 screen identifies druggable dependencies in <i>TP53</i> wild-type Ewing sarcoma.J Exp Med2018
30038712KLF5 controls glutathione metabolism to suppress p190-BCR-ABL+ B-cell lymphoblastic leukemia.Oncotarget2018
29358035EWS/FLI Confers Tumor Cell Synthetic Lethality to CDK12 Inhibition in Ewing Sarcoma.Cancer Cell2018
29515000Exploiting an Asp-Glu "switch" in glycogen synthase kinase 3 to design paralog-selective inhibitors for use in acute myeloid leukemia.Sci Transl Med2018
29508386Bepridil exhibits anti-leukemic activity associated with NOTCH1 pathway inhibition in chronic lymphocytic leukemia.Int J Cancer2018
29328122Model-assisted measuring method for periodical sub-wavelength nanostructures.Appl Opt2018
29202477CRISPR-Cas9 screen reveals a MYCN-amplified neuroblastoma dependency on EZH2.J Clin Invest2018
  • 1 - 50 of 152

Recommended Authors

Pichai Raman
Center for Data-Driven Discovery in Biomedicine, Children's Hospital of Philadelphia
Career Start Year 2006
Number of shared co-authors 10
Matti Nykter
Prostate Cancer Research Center, Tampere University and Tays Cancer Center
Career Start Year 2006
Number of shared co-authors 3
James C Costello
University of Colorado Anschutz Medical Campus
Career Start Year 2006
Number of shared co-authors 7
Joshy George
Peter MacCallum Cancer Centre
Career Start Year 2005
Number of shared co-authors 4
Adam A Margolin
Icahn School of Medicine
Career Start Year 2004
Number of shared co-authors 28
Nathalie Pochet
Broad Institute of MIT and Harvard
Career Start Year 2004
Number of shared co-authors 9
Benjamin Haibe-Kains
Princess Margaret Cancer Centre, University Health Network
Career Start Year 2004
Number of shared co-authors 4
Aik Choon Tan
Huntsman Cancer Institute, The University of Utah
Career Start Year 2003
Number of shared co-authors 8
Leslie Cope
Johns Hopkins University School of Medicine
Career Start Year 2003
Number of shared co-authors 8
Andrew V Kossenkov
The Wistar Institute
Career Start Year 2003
Number of shared co-authors 2
Jianhua Zhang
University of Texas MD Anderson Cancer Center
Career Start Year 2003
Number of shared co-authors 15
Syed Haider
Institute of Cancer Research
Career Start Year 2002
Number of shared co-authors 1
Joel S Parker
Lineberger Cancer Center, University of North Carolina
Career Start Year 2002
Number of shared co-authors 17
Habib Hamidi
Genentech Inc.
Career Start Year 2002
Number of shared co-authors 0
Michael Slifker
Fox Chase Cancer Center
Career Start Year 2002
Number of shared co-authors 1
Olivier Elemento
Meyer Cancer Center
Career Start Year 2002
Number of shared co-authors 14
Yidong Chen
The University of Texas Health Science Center at San Antonio
Career Start Year 2001
Number of shared co-authors 4
Lodewyk F A Wessels
University Medical Centre Mannheim, University of Heidelberg
Career Start Year 2000
Number of shared co-authors 8
Andrew J Gentles
Stanford Center for Biomedical Informatics Research, Stanford University
Career Start Year 1999
Number of shared co-authors 5
Celine Lefebvre
The Scripps Research Institute
Career Start Year 1999
Number of shared co-authors 1
Benedikt Brors
German Cancer Research Center (DKFZ)
Career Start Year 1997
Number of shared co-authors 5
Ole Christian Lingj??rde
University of Oslo
Career Start Year 1997
Number of shared co-authors 0
Aedin C Culhane
Dana-Farber Cancer Institute & Harvard School of Public Health
Career Start Year 1996
Number of shared co-authors 6
Sudhir Varma
Center for Cancer Research, National Cancer Institute
Career Start Year 1994
Number of shared co-authors 1
Adam B Olshen
12224University of California san francisco
Career Start Year 1993
Number of shared co-authors 10
Carlos Caldas
Cancer Research UK Cambridge Institute, University of Cambridge
Career Start Year 1992
Number of shared co-authors 12
Kevin R Coombes
Medical College of Georgia
Career Start Year 1990
Number of shared co-authors 2
Luigi Marchionni
Weill-Cornell School of Medicine
Career Start Year 1989
Number of shared co-authors 4
Yuval Kluger
Yale University School of Medicine
Career Start Year 1984
Number of shared co-authors 1
Rainer Spang
University of Regensburg
Career Start Year 1969
Number of shared co-authors 0

Collaborators

Kimberly Stegmaier
Dana-Farber Cancer Institute
Co-authored papers 42
Alexandre Puissant
Universite de Paris, INSERM, CNRS
Co-authored papers 12
Yana Pikman
Dana Farber Cancer Institute
Co-authored papers 11
Jill P Mesirov
University of California San Diego
Co-authored papers 8
Arnold J Levine
Simons Center for Systems Biology, Institute for Advanced Study
Co-authored papers 8
Pablo Tamayo
University of California San Diego
Co-authored papers 7
Giovanni Roti
University of Parma
Co-authored papers 7
William C Hahn
Broad Institute of MIT and Harvard, USA Dana-Farber Cancer Institute
Co-authored papers 6
Charles DeLisi
Co-authored papers 6
Francisca Vazquez
Broad Institute of MIT and Harvard
Co-authored papers 6
Richard M Stone
Dana Farber Cancer Institute
Co-authored papers 6
Christopher F Bassil
Duke University School of Medicine Durham
Co-authored papers 6
Lina Benajiba
Universite de Paris, Inserm CIC 1427
Co-authored papers 6
Nina Fenouille
Universite Paris Cite, INSERM, CNRS
Co-authored papers 6
Daniel J DeAngelo
Dana-Farber Cancer Institute
Co-authored papers 6
Jun Qi
Dana-Farber Cancer Institute
Co-authored papers 5
Angela Su
The Broad Institute of MIT and Harvard
Co-authored papers 5
Aviad Tsherniak
Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard
Co-authored papers 5
Federica Piccioni
Co-authored papers 5
Brian D Crompton
Co-authored papers 5
Barbara A Weir
Janssen Research and Development LLC
Co-authored papers 5
Nathanael S Gray
Harvard Medical School
Co-authored papers 4
Gaetano Sodaro
Universite Paris Cite, INSERM, CNRS
Co-authored papers 3
Raphael Itzykson
Universite Paris Cite, INSERM, CNRS
Co-authored papers 3
James E Bradner
Co-authored papers 3
Todd R Golub
Broad Institute of MIT and Harvard
Co-authored papers 3
Gad Getz
Broad Institute of the Massachusetts Institute of Technology and Harvard
Co-authored papers 3
Jesse S Boehm
Broad Institute of Harvard and MIT
Co-authored papers 3
William A Weiss
University of California san francisco
Co-authored papers 3
Jaume Mora
Pediatric Cancer Center Barcelona, Hospital Sant Joan de Deu
Co-authored papers 3
Release 1.2